Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

British Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1994, Pages 1-8

  Jacqz Aigrain E ^a   Bessa, E ^a   Medard, Y ^a   Mircheva, Y ^a   Vilmer, E ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ENZYME INHIBITOR; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHROCYTE; FRANCE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL;

6-MERCAPTOPURINE; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FRANCE; GALLIC ACID; HUMAN; MALE; METHYLTRANSFERASES; PHENOTYPE; POLYMORPHISM (GENETICS);

EID: 0028228699     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1994.tb04314.x     Document Type: Article

References (46)

1. Thiopurine methyltransferase: Structure‐activity relationships for benzoic acid inhibitors and thiophenol substrates
2. Metabolism of thiopyrimidines and thiopurines S‐methylation with S‐adenosyl‐methionine transmethylase and catabolism in mammalian tissues
3. The clinical pharmacology of 6‐mercaptopurine
4. Cellular pharmacology of 6‐mercaptopurine in acute lymphoblastic leukaemia
5. Assay of 6‐thioguanine nucleotide, a major metabolite of azathioprine, 6‐mercaptopurine and 6‐thioguanine, in human red blood cells
6. Assay of 6‐thioinosinic acid and 6‐thioguanine nucleotides, active metabolites of 6‐mercaptopurine, in human red blood cells
7. A biochemical mechanism for the delayed cytotoxic reaction of 6‐mercaptopurine
8. Ribonucleotides and ribonucleosides as methyl acceptors for SAM
9. Genetic variation in response to childhood acute lymphoblastic leukaemia
10. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotides
11. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
12. Pharmacogenetics of methyl conjugaison and thiopurine drug toxicity
13. Pharmacogenetics of human thiopurine methyltransferase: Kidney erythrocyte correlation and immunotitration studies
14. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity
15. Variable 6‐mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
16. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism
17. Are children with lymphoblastic leukaemia given enough 6‐mercaptopurine
18. Human lymphocyte thiopurine methyltransferase pharmacogenetics: Effect of phenotype on 6‐mercaptopurine induced inhibition of mitogen stimulation
19. Genetically determined polymorphisms in drug oxidation
20. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties
21. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocystic leukemia in children
22. 6‐mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity
23. 6 MP bioavailability
24. Variable bioavailability of oral 6‐mercaptopurine
25. Childhood lymphoblastic leukaemia: sex difference in 6‐mercaptopurine utilization
26. Importance of 6‐mercaptopurine dose in lymphoblastic leukemia
27. Difference in prognosis for boys and girls with acute lymphoblastic leukemia
28. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6‐mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia
29. Variability in caffeine metabolism
30. Effect of allopurinol on cafeine disposition in man
31. Human liver xanthine oxidase: nature and extent of individual variation
32. Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 activities
33. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver‐erythrocyte correlation and presence of isozymes
34. Thiopurine methyltransferase: Aromatic thiol substrates and inhibition by benzoic acid derivates
35. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase‐deficient child with acute lymphoblastic leukemia
36. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population
37. Statistical method for assessing agreement between two methods of clinical measurement
38. Human kidney thiopurine methyltransferase: purification and biochemical properties
39. Interethnic difference in thiopurine methyltransferase activity
40. Thiopurine methyltransferase activity in a sample population of black subjects in Florida
41. Thiopurine S‐methyltransferase activity in a Chinese population
42. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population
43. Thiopurine methyltransferase activity to assess azathioprine myelotoxicity in renal transplant recipients
44. Azathioprine‐induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
45. Azathioprine‐induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
46. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients